Semantic interoperability for an AI-based applications platform for smart hospitals using HL7 FHIR使用HL7 FHIR的基于AI的智能医院应用平台的语义互操作性JOURNAL OF SYSTEMS AND SOFTWAREIF4.12024-09-012OAAI
SECUKINUMAB IN THE MANAGEMENT OF PSORIATIC ARTHRITIS IN GREECE: A BUDGET IMPACT ANALYSISVALUE IN HEALTHIF62016-11-010OAAI
COST-UTILITY ANALYSIS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE IN GREECEVALUE IN HEALTHIF62016-11-011OAAI
A BUDGET IMPACT ANALYSIS OF SECUKINUMAB IN THE MANAGEMENT OF ANKYLOSING SPONDYLITIS IN GREECEVALUE IN HEALTHIF62016-11-010OAAI
COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECEVALUE IN HEALTHIF62016-11-011OAAI
BUDGET IMPACT ANALYSIS OF PANOBINOSTAT - BORTEZOMIB AND DEXAMETHASONE, AS 3RD OR 4TH LINE OF TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN GREECEVALUE IN HEALTHIF62016-11-010OAAI
Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in GreeceANNALS OF ONCOLOGYIF65.42016-10-010OAAI
ECONOMIC EVALUATION OF OMALIZUMAB COMPARED WITH STANDARD THERAPY IN THE TREATMENT OF SEVERE ALLERGIC ASTHMA IN ADULT PATIENTS IN GREECE: A COST EFFECTIVENESS ANALYSIS BASED ON CLINICAL TRIAL AND REAL-WORLD DATAVALUE IN HEALTHIF62014-11-012OAAI
ASSOCIATION OF HYPOGLYCEMIA WITH DIFFERENT ORAL ANTIDIABETIC TREATMENTS AND ITS IMPACT ON QUALITY OF LIFE AND DISEASE CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (THE HYPO STUDY)VALUE IN HEALTHIF62014-11-010OAAI
ECONOMIC EVALUATION OF VALSARTAN VERSUS OLMESARTAN ADDITION TO AMLODIPINE AND HYDROCHLOROTHIAZIADE SINGLE-PILL TRIPLE ANTIHYPERTENSIVE THERAPYVALUE IN HEALTHIF62014-11-011OAAI
THE DIRECT AND INDIRECT COSTS OF WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME) IN GREECEVALUE IN HEALTHIF62014-11-011OAAI
THE PREVALENCE OF HYPOGLYCEMIA AND ITS IMPACT ON THE QUALITY OF LIFE OF TYPE 2 DIABETES MELLITUS PATIENTS IN GREECE (THE HYPO STUDY)VALUE IN HEALTHIF62014-11-012OAAI
HEALTH CARE COST OF TYPE 2 DIABETES PATIENTS IN GREECE: SUB-POPULATION ANALYSISVALUE IN HEALTHIF62013-11-010OAAI
HEALTH CARE COST OF CONTROLLED VERSUS UNCONTROLLED TYPE 2 DIABETES PATIENTS IN GREECEVALUE IN HEALTHIF62013-11-010OAAI
BUDGET IMPACT ANALYSIS OF DEFERASIROX IN THE TREATMENT OF NON TRANSFUSION DEPENDENT THALASEMIA IN GREECEVALUE IN HEALTHIF62013-11-011OAAI
PRELIMINARY RESULTS OF A MULTICENTER OBSERVATIONAL STUDY OF TREATMENT COMPLIANCE WITH FREE-COMBINATION VERSUS FIXED COMBINATION TREATMENT IN TYPE II DIABETES MELLITUS PATIENTS IN GREECE (LESS STUDY)VALUE IN HEALTHIF62012-11-011OAAI
ECONOMIC EVALUATION OF A SINGLE-PILL TRIPLE COMBINATION WITH VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AGAINST ITS DUAL COMPONENTS IN GREECE. THE GENERIC SUBSTITUTION CASEVALUE IN HEALTHIF62012-11-011OAAI
ECONOMIC EVALUATION OF VILDAGLIPTIN COMPARED TO GLIMEPIRIDE AS ADD-ON TO METFORMIN FOR THE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS IN GREECEVALUE IN HEALTHIF62012-11-012OAAI
NUMBER NEEDED TO TREAT (NNT) AND COST ESTIMATION TO ACHIEVE A MAJOR MOLECULAR RESPONSE (MMR) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS IN GREECEVALUE IN HEALTHIF62012-11-010OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向